During a study of cortisol metabolism in advanced cancer and other disease states (1), we observed in patients receiving DPH 1 therapy for convulsive seizures an abnormal pattern of excretion of cortisol metabolites in urine. This abnormal pattern was characterized by increased urinary output of the polar unconjugated metabolite 6-OHF, suggesting an interference with extraadrenal metabolism of cortisol by DPH. We wished to pursue this finding in more detail for two reasons: 1) An interrelationship among convulsive seizures, the anticonvulsant action of DPH, and pituitary-adrenal function has been demonstrated by several investigators, but interpretation of this is unclear. Woodbury, Timiras, and Vernadakis have shown that cortisol and DPH are antagonistic in their effect on brain excitability in rats; treatment with cortisol enhances, whereas DPH depresses, brain excitability (2) . These investigators believed that DPH administration to rats stimulates adrenocortical secretion, * Submitted for publication January 22, 1964 ; accepted May 28, 1964. Reported in abstract form in Clinical Research 1963, 11, 230. t Present address: Christ Hospital, Cincinnati, Ohio. 1 Glossary of trivial names and abbreviations: diphenylhydantoin (DPH) =5,5'-diphenylhydantoin; 6-hydroxycortisol (6 -OHF) = 6a (/3), 11,/, 17a, 21 -tetrahydroxy -4 -pregnene-3,20 -dione; 17-OHCS = 17-hydroxycorticosteroids; ACTH = adrenocorticotrophic hormone; methopyrapone (Metopirone, Ciba Pharmaceutical Co., Summit, N. J.) =2-methyl-1,2-di-(3-pyridyl)-1-propanone. Tetrahydro derivatives: THF (tetrahydrocortisol) = 3a,11,, 17a,21-tetrahydroxy-5/8-pregnan-20-one; allo-THF (allotetrahydrocortisol) = 3a,11/3,17a,21-tetrahydroxy-5a-?pregnan-20-one; THE (tetrahydrocortisone) = 3a,17a,21-trihydroxy-5p-pregnan-11,20-dione. Cortol = 3a, 11,8,17a,20a (/3),21-pentahydroxy-5/3-pregnane; cortolone = 3a,17a,20a (/3) ,21-tetrahydroxy-5/8-pregnan-11-one; 17-KS = 17-ketosteroids; 1 1-hydroxyetiocholanolone = 3a,1j1/-dihydroxy- 5 ,B-androstan-17-one; dehydroisoandrosterone = 3/3-hydroxy-5-androstene-17-one; TPNH = reduced triphosphopyridine nucleotide; o,p'DDD = 2,2-bis (2-chlorophenyl,4-chlorophenyl) 1,1-dichloroethane. since a) adrenal hypertrophy was observed in intact rats and b) in adrenalectomized rats treated with DPH a more profound decrease in brain excitability was demonstrated than in intact rats. Goncharov has observed that acute administration of DPH to dogs and guinea pigs increases adrenocortical output of cortisol (3) . Reports by Staple (4) and Bonnycastle and Bradley (5) have, however, indicated an inhibition of pituitary-adrenal secretion after chronic DPH treatment of mice and rats.
In humans also cortisol has been shown to enhance brain excitability (6) . After chronic DPH therapy to patients, excretion of corticosteroids in urine is reported to decrease (7, 8) after an initial increase (7) . These findings have led to the suggestion that the decrease in brain excitability induced by DPH might be mediated partially through adrenocortical suppression. However, levels of 17-OHCS in plasma from patients treated with DPH are usually normal (8, 9) , as are responses to ACTH (8, 9) and rates of disappearance from plasma of infused cortisol (8) . These observations detract from the possibility that direct adrenocortical suppression plays a significant role in therapeutic effectiveness of DPH. Recently, however, Krieger has demonstrated that control subjects treated with DPH manifest a reduced response in the methopyrapone test, which suggests an interference with ACTH release (10) .
2) The increased excretion of 6-OHF produced by DPH appears to be similar to that we have observed in patients with advanced cancer and certain terminal illnesses (1) as well as to that reported after estrogen therapy (11), during pregnancy (12) , and in newborn infants (13) .
Thus we hoped that further investigation into the nature of this alteration in cortisol metabolism induced by DPH would contribute information bearing on the two aforementioned problems. The purpose of this paper is to describe results of 1824 studies dealing with in vivo administration of DPH to human subjects.
Methods
Subj ects studied were normal volunteers and patients in the Veterans Administration Hospital, Cincinnati, Ohio. DPH was administered as the commercially available product Dilantin,2 given in divided doses two or three times per day. Twenty-four-hour urine collections were obtained on ice and samples frozen until subsequent chemical analysis, a period of up to several weeks.
The radioactive cortisol-4-C1' (approximate SA, 69 pc per mg) was obtained commercially.3 Radio paper chromatography of this material demonstrated only one radioactive peak with a mobility comparable to cortisol. The cortisol-4-C"4, 0.5 /Ac, dissolved in 1 to 2 ml of ethanol, was diluted with 150 ml of normal saline and infused intravenously over 10 to 15 minutes, followed by a flushing of the bottle and tubing with another 150 ml of saline. The infusions were given at about 9 a.m. Twenty-four-hour urine collections were begun just before the infusion. ACTH Chemical methods. Analysis of 17-OHCS in urine was performed according to the general procedure of Silber and Porter (14) with certain modifications. In preparation for hydrolysis the urinary sample was diluted 50% with distilled water, adjusted to pH 4.8 with acetate buffers, and a small amount of chloroform added. fi-Glucuronidase (Ketodase)4 was added initially at a concentration of 500 U per ml of urine and later at higher concentrations as described in the Results. Butanol (0.7 ml) was added to a sample of chloroform extract (20 ml) before extraction with phenylhydrazine color reagent. Color development was allowed to proceed overnight at room temperature to minimize differences in chromogenic intensity between THF and THE (15 Extraction with ethyl acetate and washes with alkali and acid were performed as described by the above 2 Parke, Davis, Detroit, Mich. 3 New England Nuclear Corp., Boston, Mass. 4 Warner-Chilcott Div., Morris Plains, N. J.
workers. An atmosphere of nitrogen, however, was not found necessary. After evaporation of the ethyl acetate in vacuo, the final extract was made up to a volume of 10 ml of ethyl acetate: methanol mixture (1: 1). Samples of this were chromatographed on strips of Whatman, 3MM paper, 3 cm wide, in the solvent system, ethyl acetate: chloroform: methanol: water, 1: 3: 2: 2, for 3 to 4 hours. Quantitation was done routinely by densitometry of the strip after staining with blue tetrazolium (17) Further identification of 6-OHF from urine extracts was performed in several instances by eluting unstained 6-OHF after chromatography, and examining 1) UV absorption spectra in methanol and 2) absorption spectra after reaction with sulfuric acid. These agreed with pure standards. Both 6a-OHF and 6#-OHF exhibit absorption maxima at 236 mu in methanolic solution. The sulfuric acid absorption curves of these two compounds, however, were different, and the two compounds could be recognized accordingly. 6a-OHF has a peak at 280 m/l, whereas this is absent with 6,p-OHF. Conversely, 6j#-OHF has a peak at 335 my, and 6a-OHF does not.
In several instances the amounts of 6a-OHF and 619-OHF were quantitated by differential absorption curves. The amount of 6a-OHF varied from a trace to 56%o without any correlation with diagnosis or treatment of the patient. Quantitating these separate isomers did not seem to be of value. Results for 6-OHF pertain to the total of 6a-and 6,8-OHF. Another more polar compound was usually observed running about halfway between the origin and 6-OHF on the paper strips. This compound reacted with blue tetrazolium and absorbed UV light. The concentration of this substance correlated directly with that of 6-OHF. As demonstrated subsequently in the studies with cortisol-4-C14, this polar unknown compound was a metabolite of cortisol, but its identification has not been accomplished. Incubation of several urine samples with f-glucuronidase before extraction did not increase the yield of 6-OHF, which is similar to the observation of Frantz and associates (16) .
Determination of THF, allo-THF, and THE. These metabolites were analyzed from chloroform extracts of ,3-glucuronidase hydrolyzed urine samples (10 to 40 ml).
Extracts were chromatographed on paper strips in duplicate for 24 hours in the system, toluene: methanol: water (16: 3: 1). THF, allo-THF, and THE were located by staining a small inner strip with blue tetrazolium. The three metabolites were eluted from the remaining paper with absolute methanol, and the phenylhydrazinesulfuric acid color reaction was performed on the eluate. Standards of THE and THF were chromatographed on adj acent strips, and the unknown samples were quantitated according to the standards. Final calculations also took into account an average loss from extraction as determined by adding standards to various urine portions. Duplicate samples through the entire procedure agreed within 10%.
17-KS and creatinitte. Levels of 17-KS were determined by the procedure of Drekter and co-workers (18) . Urinary levels of creatinine were measured according to the technique of Folin and Wu (19) .
Procedures with cortisol-4-C". ,B-Glucuronidase hydrolysis was similar to that described under the chemical analysis for 17-OHCS in urine. Acid hydrolysis was performed by acidification of the urine to pH 1 with 50% sulfuric acid and incubation for 24 hours at 370 C in the dark. When no hydrolysis was performed, urine was buffered with acetate to pH 4.8 before solvent extraction. Extraction with chloroform or ethyl acetate was performed in a manner similar to that described for the chemical method for 17-OHCS and 6-OHF, respectively. Solvents were evaporated on vacuum flash evaporators or in vacuo under a stream of filtered air and made up to volume with absolute methanol.
In the fractional separation by paper chromatography (Table II) , ethyl acetate extracts of urine samples (5 to 7% of 24-hour output), hydrolyzed by ,3-glucuronidase, were chromatographed on paper in the system described under the chemical procedure for 6-OHF. The mobile phase was allowed to run to the edge of the paper, allowing separation of six major fractions as predetermined by chromatographing appropriate standards. With each run of urine extracts two adjacent strips with standards were used and stained with blue tetrazolium and phosphomolybdic acid, respectively. A 2-mm wide strip also was cut from the center of each strip containing a urine extract and stained with blue tetrazolium. As shown in Table II , six major fractions could be identified; they were divided, cut up into smaller pieces, and eluted with absolute methanol. The methanol extracts were evaporated and made up to a known volume with methanol. Samples of each fraction were taken for counting of C14. After removing the sample from fraction six, the residual extract was evaporated to dryness and subsequent chromatography performed on a Florisil column to separate the 17-KS and the tetrahydro compounds with 4%o and 25%o concentrations of methanol in chloroform, respectively (20) . The column eluates were evaporated, made up to volume with methanol, and samples taken for counting C14.
Cortisol secretion rates (CSR) were determined from chloroform extracts of urine samples (10 to 50 ml) incubated with /3-glucuronidase. The extracts were chromatographed on paper strips in duplicate for 24 hours in the system, toluene: methanol: water (16: 3: 1). THF and THE were located by staining a thin inner strip with blue tetrazolium, and the THF and THE were eluted with methanol. The phenylhydrazine-sulfuric acid color reaction was performed on one sample of the eluate and C" counted on another. The final specific activities of THF and THE usually agreed within 10%. In urine samples from two of the six patients, the specific activities of THF and THE varied widely despite rechromatography. In these instances new extracts were chromatographed in the system, iso6ctane: tertiary butanol:water (10:5:9), the THF and THE eluted, reduced with potassium borohydride, and oxidized with periodic acid. The final product, 11-hydroxyetiocholanolone, in each case was chromatographed on separate paper strips in the system, iso6ctane: toluene:methanol: water (3:1: 3:1) and eluted with methanol. Specific activity was determined by the Zimmerman reaction and counting on respective samples. Specific activities of the final 11-hydroxyetiocholanolone preparations, expressed as THF and THE, agreed within 10%o. In four subjects, during DPH therapy, specific activities of 6-OHF were determined by the same method to isolate 6-OHF as in the chemical determination of this metabolite. Instead of densitometry, however, the 6-OHF was eluted from the paper chromatographic strip and specific activity determined by the phenylhydrazine-sulfuric acid color reaction and counting of the C". The specific activities (disintegrations per minute X 10' per micromole) of the 6-OHF in these four instances were 2.96, 0.86, 1.64, and 1.36 and compared closely to the average specific activities of the THF and THE, 2.86, 0.92, 1.66, and 1.31, respectively. CSR was calculated by dividing the average specific activities of the two or three isolated metabolites into dose of radioactivity injected.
All counting of C1" was performed on a Packard TriCarb liquid scintillation spectrometer with a usual efficiency of about 60%o. Methanolic samples, 0.1 to 0.3 ml, of the various eluates were added to 10 ml of toluene scintillation solution [4 g of 2,5-diphenyloxazole andDIPHEX\YLHYDANTOIN AND CORTISOL METABOLISM
Results
Inhibition of in vitro /8-glucuronidase hydrolysis in urine from patients receiving DPH. During the course of this investigation we noted that the amount of radioactivity extracted with ethyl acetate or chloroform from urine of patients receiving DPH and cortisol-4-C' was unexpectedly low.-These urine samples had been incubated with P-glucuronidase at a concentration of 500 U per ml of urine before extraction. The possibility that the poor recoveries of radioactivity were due to insufficient hydrolysis of the cortisol metabolites by /8-glucuronidase was tested by adding increasing amounts of enzyme to urine samples that were subsequently extracted with chloroform or ethyl acetate. 5 As can be seen in Figure 1 , maxi-mal recovery of radioactivity was not achieved in urine from two normal subjects treated with DPH until the enzyme concentration approached 4,000 U per ml of urine, employing either chloroform or ethyl acetate for extraction, whereas in urine collected during control periods maximal hydrolysis was obtained with an enzyme concentration of 1,000 U per ml of urine.
It may also be noted in Figure 1 that when chloroform extraction was employed, recovery of radioactivity from urine during the DPH treatment period was considerably below that from urine during the control period, despite maximal enzyme concentration. This is consistent with an absolute decrease in cortisol metabolites in the chloroform-extractable fraction induced by DPH, as will be re-emphasized subsequently. extraction chemical method for 17-OHCS. The 17-OHCS values averaged 45% higher with an enzyme concentration of 4,000 U per ml than with 500 U per ml in four subjects receiving DPH. During the control period in these four subjects, the chemical values using an enzyme concentration of 1,000 U per ml of urine were slightly higher than with 500 U per ml, average increase 16%. Thus, in all analyses pertaining to 83-glucuronidase hydrolysis, concentration of enzyme employed was 1,000 U per ml of urine from control periods and 4,000 U per ml of urine from samples of subjects receiving DPH. Urine samples that had been collected early in the study and initially analyzed with a lower enzyme concentration were repeated, or in a few instances an average correction factor, based upon the previously mentioned data, was applied. Steroid excretion. In Figure 2 weekly steroid excretion is presented for a representative normal subject given DPH, 300 mg per day for 6 weeks. The most marked effect of DPH was gradually increasing the daily output of 6-OHF from about 0.2 mg up to 1.9 mg. On the other hand, excretion of 17-OHCS and 17-KS in urine decreased slightly. The alteration in cortisol metabolism can be expressed by the ratio of 6-OHF: 17-OHCS, which increased tenfold in this subject.
In Figure 3 * All ethyl acetate extractions were performed after addition of sodium sulfate to urine sample (approximately 5 to 7% of 24-hour output), as described under Methods. The solvent system used in the paper chromatography was the same as that described in the chemical determination of t The dose and duration of therapy with DPH were the same as those shown in Table IV. $ Further fractionated into a) and b) by Florisil column chromatography.
6-OHF excretion (11).
A slight rise in 6-OHF output occurred, which was much less than that after DPH. Moreover, excretion of 17-OHCS decreased slightly, in contrast to the rise observed after DPH.
In Table I changes in steroid excretion are summarized for 11 subjects receiving DPH for 2 to 8 weeks. A consistent elevation in output of 6-OHF, ranging from 2.5-to 10-fold, was found in all subjects. Excretion of 17-OHCS in urine decreased slightly in 7 of the 11 subjects, increased in 2, and was essentially unchanged in 2. The Table I . may be noted from Figure 1) ; and 2) an increase, Excretion of tetrahydro derivatives. In view about twofold, in polar unconjugated metabolites of the changes in the tetrahydro fraction, it was extracted by ethyl acetate. There were no sig-considered of interest to compare excretion of innificant differences noted in unconjugated chloro-dividual tetrahydro metabolites. The results, form-extractable fractions or acid-hydrolyzable Table III , are expressed in terms of ratios of indifractions.
vidual metabolites to the sum total or to each In Table II changes determined by a more dis-other. The ratios of THF: total and THF: THE crete fractionation system are depicted from urine increased during DPH therapy, whereas the ratios samples of the same three subjects. In these ex-allo-THF: total and THE: total tended to decrease. periments extracts of urine that had been hydro-CSR, Table IV . CSR were measured in six lyzed with 8-glucuronidase and extracted with subjects, five of whom were normal, during both ethyl acetate were fractionated as described in the control and DPH periods. An increase, of relaMethods section. The principal changes after tively small degree, was found in four of the six DPH therapy were the decrease in tetrahydro me-subjects. In one subject, G.B., there was an intabolites, THF, allo-THF, and THE, and the in-significant decrease and in the remaining subject, crease in 6-OHF and an unidentified polar un-no change. known. No consistent differences were noted in ACTH administration, Table V . ACTH gel the cortol-cortolone fractions or in the 17-KS.
was given to two normal subjects and patient F.J. t The base-line excretions and ratios used in the compilation of these data were the averages for the respective study periods as-depicted in Table I . The increases in output of 6-OHF after ACTH were markedly augmented while the subjects were receiving DPH1. The ratios of 6-OHF:
17-OHCS also were enhanced considerably. A slightly greater increase in excretion of 17-OHCS was found in subjects J.B. and F.J. These changes, coupled with the considerably higher increase in output of 6-OHF, indicate a greater adrenal secretary responsiveness in these two subjects when receiving DPH. Finally, steroid excretion was measured in 6 additional patients with convulsive disorders who had received long-term DPH treatment, in contrast to the previously mentioned 11 subjects. Output of 6-OHF was increased above normal (Table VI) , the degree of which was comparable to that found in the subjects on short-term DPH treatment (Table I) . Output of 17-OHCS, conversely, was in the low normal range. Ratios of 6-OHF: 17-OHCS were markedly abnormal, ranging from 0.20 to 1.37, the degree of which tended to be greater than in normal subjects receiving short-term DPH.
Discussion
The principal results of this investigation document an extra-adrenal alteration in cortisol metabolism induced by administration of DPH to human subjects. The alteration was characterized by an increased proportion of cortisol metabolized to polar unconjugated metabolites and a corresponding decreased proportion metabolized via A-ring reduction and glucuronic acid conjugation. The polar unconjugated metabolites consisted principally of 6-OHF, and in somewhat lesser amounts, another, as vet unidentified, polar compound. Interestingly, the alteration in tetrahydro derivatives included an increase in the proportion of THF to THE and to the total tetrahydro metabolites.
The major alterations were observed in radioactive metabolites in urine after administration of cortisol-4-C14 in vivo, indicating that the changes truly reflected metabolism of cortisol. Furthermore, the changes were found in one patient with Addison's disease and in another bilaterally adrenalectomized, indicating that the metabolic alterations occurred outside of the adrenal glands. Presumably the major site is liver, since it is well known to be the chief organ responsible for the greatest proportion of cortisol metabolism. Also the study by Lipman, Katz, and Jailer, employing human tissue incubation in vitro, demonstrated more 6,8-hydroxylation activity in liver than in other tissues (23) .
That other steroids may have been altered by DPH administration was suggested by reduction in 17-KS excretion. Since neither the radioactive 17-KS metabolites of cortisol (Table II) (8, 9) or reduced (9) (7) .
An incidental but important finding was that urine from subjects treated with DPH requires a greater concentration of /8-glucuronidase than usual to achieve maximal hydrolysis of steroidglucuronide conjugates. This indicates an inhibition of ,B-glucuronidase by DPH or its major metabolite, 5-(p-hydroxyphenyl) -5-phenylhydantoin (24) , which is conjugated with glucuronic acid (25) . Although the mechanism of inhibition was not studied, it is conceivable that it might be a competitive one as noted with the glucuronide of acetylsalicylic acid (26 (11, 12, 16, 23, 27) and by Ulstrom, Colle, Burley, and Gunville (13) . The latter group noted that 6-OHF was a major metabolite of cortisol in newborn infants. The former group initially observed an increased output of 6-OHF in pregnancy and subsequently attributed increased formation of 6-OHF to inhibition of cortisol A-ring reduction brought about by a high level of estrogen and a resultant interference with TPNH production.
The finding in the current study of a proportionate decrease in tetrahydro derivatives is consistent with the postulate of a partial block in A-ring reduction. It does not seem likely, however, that this aberration is due to an estrogenic effect, since after DPH therapy there is no increase in plasma cortisol binding, as shown by normal levels of 17-OHCS in plasma (8, 9) . Effects of other hormones, testosterone, ACTH, and thyroxine, might be considered. Testosterone depresses cortisol A-ring reduction (28) (29) (30) but does not increase 6-OHF excretion (11) . ACTH has been reported to enhance 6-OHF excretion to some degree (16) . In the present study, however, little change was noted in the ratio of 6-OHF: 17-OHCS after ACTH when subjects were not receiving DPH. Thyroxine is known to be displaced by DPH from thyroxine-binding globulin (31) , but an excess of thyroxine would be expected to increase the proportion of THE rather than reduce it.
Thus current evidence indicates that the alteration in cortisol metabolism induced by DPH is not mediated through effects by these hormones. Perhaps DPH, or its major metabolite (24) , may interfere directly with cortisol A-ring reduction or TPNH production.
Whether there is any relation between pharmacological action of DPH and this aberration in cortisol metabolism remains speculative. Levels of 17-OHCS in plasma are normal during DPH therapy (8, 9) . Conceivably DPH might interfere with cortisol metabolism in brain as well as liver. Such a concept would require a reduction in cortisol activity locally, since cortisol enhances brain excitability. How this could occur in conjunction with the metabolic alteration is questionable. It is of interest, however, that other known effects of DPH are consistent with a reduction in cortisol activity, namely, lymphoid hyperplasia (32, 33) , protein anabolism (34), dermal chemical response (35) , and a suggestion of amelioration of Cushing's syndrome despite high levels of 17-OHCS in urine (36) .
Summary
The effect of diphenylhydantoin administration on cortisol metabolism was investigated in human subjects by analyzing cortisol metabolites in urine. Diphenylhydantoin caused a net increase in ex-1833 cretion of 6-hydroxycortisol and an unconjugated polar metabolite concomitant with a relative decrease in conjugated tetrahydro derivatives. Similar results were found in two patients with adrenal insufficiency. Fractionation studies after administration of cortisol-4-C"4 to subjects treated with diphenylhydantoin confirmed these changes and demonstrated them to be the major alterations in cortisol metabolism induced by diphenylhydantoin.
Administration of exogenous ACTH enhanced the alteration in cortisol metabolism in diphenylhydantoin-treated subjects.
Cortisol secretion rates increased slightly in four of six subjects treated with diphenylhydantoin for 5 to 8 weeks. In addition, one patient with brain trauma showed a marked increase in steroid excretion indicative of a true rise in cortisol secretion. In other patients receiving longterm diphenylhydantoin therapy cortisol secretion appeared to be reduced.
Output of total 17-ketosteroids decreased slightly in normal subjects receiving diphenylhydantoin but not in patients with adrenal insufficiency, which suggested an effect on the metabolism of 11-deoxy, 17-ketosteroids produced in the adrenals.
An incidental but important finding in the study was that of an in vitro inhibition of /3-glucuronidase in urine from subjects receiving diphenylhydantoin. Thus a fourfold increase in enzyme concentration was necessary in these samples for maximal hydrolysis, compared to control urine samples. We conclude that diphenylhydantoin alters extra-adrenal metabolism of cortisol and probably 17-ketosteroids as well. This effect may be related to the pharmacological activity of diphenylhydantoin.
